登录 | 注册    关注公众号  
微信公众号
搜索
 >  Antibody>Cetuximab >CEB-Y31

Anti-Cetuximab Antibody (AY31) (Non-Neutralizing)

抗体来源(Source)

Mouse monoclonal antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with Cetuximab F(ab')2.

亚型(Isotype)

Mouse IgG1/kappa

特异性(Specificity)

Recognizes Cetuximab specifically, no cross reactivity with other humanized antibodies.

纯度(Purity)

>95% as determined by SDS-PAGE.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. 4-8°C for 12 months in lyophilized state;
  2. -70°C for 12 months under sterile conditions after reconstitution.
 

电泳(SDS-PAGE)

Cetuximab SDS-PAGE

Anti-Cetuximab Antibody (AY31) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

 

活性(Bioactivity)-ELISA

Cetuximab ELISA

Anti-Cetuximab Antibodies bridging ELISA for Anti-Drug Antibody (ADA) assay development.Immobilized cetuximab at 1 µg/mL, add increasing concentrations of Anti-Cetuximab Antibody (AY31) (Cat. No. CEB-Y31, 10% human serum) and then add biotinylated cetuximab at 2 µg/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 39 ng/mL.

Protocol

Cetuximab ELISA

Demonstration of the specificity of Anti-Cetuximab Antibody (AY31) (Cat. No. CEB-Y31) to the cetuximab.

Protocol

Cetuximab ELISA

Measured by its neutralizing ability in a functional ELISA. Immobilized cetuximab at 2 μg/mL (100 μL/well) can bind pre-mixed Anti-Cetuximab Antibody (AY31) (Cat. No. CEB-Y31) and Biotinylated Human EGFRvIII, His,Avitag (Cat. No. EGR-H82E0) with a inhibition rate of 0%.

Protocol

 

活性(Bioactivity)-SPR

Cetuximab SPR

Anti-Cetuximab Antibody (AY31) (mouse IgG1, Cat. No. CEB-Y31) captured on CM5 chip via anti-mouse antibodies surface, can bind human cetuximab with an affinity constant of 0.421 nM.

Protocol

 

背景(Background)

Cetuximab is an epidermal growth factor receptor binding FAB. Cetuximab is composed of the Fv (variable; antigen-binding) regions of the 225 murine EGFr monoclonal antibody specific for the N-terminal portion of human EGFr with human IgG1 heavy and kappa light chain constant (framework) regions.

 

前沿进展

 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定